NewsRx

Search our medical news database

Arpida, Ltd.

Data confirm potent activity of AR-709 against multidrug-resistant respiratory tract infections

Published in Law and Health Weekly, June 24th, 2006

Arpida, Ltd., (ARPN) a Swiss anti-infectives company, announced positive results from in vitro microbiological studies conducted with AR-709, a broad spectrum, bactericidal antibiotic that Arpida is developing for the treatment of upper and lower respiratory tract infections (RTI) contracted in the community setting.

AR-709 is in the investigational new drug (IND) enabling stage and is expected to enter human clinical trials in 2006.

The in vitro studies, which are being reported, comprised a total of 451 Streptococcus pneumoniae clinical isolates and were conducted by professor Peter Appelbaum at Hershey Medical Center, Pennsylvania and...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook